The present invention is directed to the area of implantable stimulation systems and methods of making and using the systems. The present invention is also directed to a lead introducer for facilitating insertion of implantable stimulation leads into patients, as well as methods of making and using the lead introducers and stimulation leads.
Implantable electrical stimulation systems have proven therapeutic in a variety of diseases and disorders. For example, spinal cord stimulation systems have been used as a therapeutic modality for the treatment of chronic pain syndromes. Peripheral nerve stimulation has been used to treat chronic pain syndrome and incontinence, with a number of other applications under investigation. Functional electrical stimulation systems have been applied to restore some functionality to paralyzed extremities in spinal cord injury patients.
Stimulators have been developed to provide therapy for a variety of treatments. A stimulator can include a control module (with a pulse generator), one or more leads, and an array of stimulator electrodes on each lead. The stimulator electrodes are in contact with or near the nerves, muscles, or other tissue to be stimulated. The pulse generator in the control module generates electrical pulses that are delivered by the electrodes to body tissue.
One aspect is a lead introducer that includes an integrated sheath/needle including a splittable sheath having a length and a proximal end region and configured to split along the length of the splittable sheath into a first portion and a second portion, the splittable sheath defining a sheath lumen, a needle having a length and a proximal end region, the needle defining an open channel extending along the length of the needle, wherein the needle extends through the sheath lumen of the splittable sheath, and a hub coupled to the proximal end regions of the splittable sheath and the needle and configured to split into a first portion and a second portion, the hub defining a port and a hub lumen extending from the port and in communication with the open channel, wherein the needle is permanently attached to the first portion of the hub so that when the hub is split into the first and second portions, the needle remains attached to the first portion of the hub.
In at least some aspects, the hub includes a body and at least two tabs extending from the body, wherein the hub is configured to split, along with the splittable sheath, using the at least two tabs. In at least some aspects, the hub includes a small-bore connector coupled to the body and forming a portion of the port and hub lumen. In at least some aspects, the needle defines a slot along the length of the needle and configured for lateral release of a lead from the open channel of the needle.
In at least some aspects, the lead introducer further includes a needle stylet configured for insertion into the open channel of the needle. In at least some aspects, the needle stylet includes a stylet body and a handle coupled to the stylet body. In at least some aspects, the needle of the integrated sheath/needle includes a body having a length, wherein the body defines two opposing ends that are separated from each other along the length of the body to define a slot. In at least some aspects, the stylet body includes a cylindrical portion and a stiffening portion extending along at least a portion of the cylindrical portion, wherein the stiffening portion is configured to fit in the slot of the needle of the integrated sheath/needle.
In at least some aspects, the needle is permanently attached to the first portion of the splittable sheath so that when the splittable sheath is split into the first and second portions, the needle remains attached to the first portion of the splittable sheath. In at least some aspects, the first portion of the splittable sheath is permanently attached to the first portion of the hub so that when the hub is split into the first and second portions, the first portion of the splittable sheath remains attached to the first portion of the hub. In at least some aspects, the second portion of the splittable sheath is permanently attached to the second portion of the hub so that when the hub is split into the first and second portions, the second portion of the splittable sheath remains attached to the second portion of the hub.
Another aspect is a lead introducer that includes an integrated sheath/needle including a splittable sheath having a length and a proximal end region and configured to split along the length of the splittable sheath into a first portion and a second portion, the splittable sheath defining a sheath lumen, and a needle having a length and a proximal end region and permanently attached to the first portion of the splittable sheath so that when the splittable sheath is split into the first and second portions, the needle remains attached to the first portion of the splittable sheath, the needle defining an open channel extending along the length of the needle.
In at least some aspects, the lead introducer further includes a hub coupled to the proximal end regions of the splittable sheath and the needle, the hub defining a port and a hub lumen extending from the port and in communication with the open channel of the needle, the hub including a body and at least two tabs extending from the body, wherein the hub is configured to split, along with the splittable sheath, using the at least two tabs. In at least some aspects, the needle of the integrated sheath/needle defines a slot configured for lateral release of a lead from the open channel of the needle.
In at least some aspects, the lead introducer further includes a needle stylet configured for insertion into the open channel of the needle. In at least some aspects, the needle of the integrated sheath/needle includes a body having a length, wherein the body defines two opposing ends that are separated from each other along the length of the body to define a slot. In at least some aspects, the needle stylet includes a stylet body and a handle coupled to the stylet body, wherein the stylet body includes a cylindrical portion and a stiffening portion extending along at least a portion of the cylindrical portion, wherein the stiffening portion is configured to fit in the slot of the needle of the integrated sheath/needle.
Yet another aspect is a lead introducer that includes a splittable sheath including a sheath body and a sheath hub coupled to the sheath body, the sheath body having a length and a proximal end region and configured to split along the length of the sheath body into a first portion and a second portion, the splittable sheath defining a sheath lumen; an outer needle including a body and a needle hub coupled to the body, wherein the outer needle is configured for insertion into the sheath lumen, the body and needle hub defining an open channel and a slot extending along a length of the outer needle and configured for lateral release of a lead disposed in the open channel through the slot; and a lead guide configured for insertion over at least a portion of the needle hub to cover a portion of the slot to facilitate insertion of the lead into the open channel of the outer needle.
A further aspect is an insertion kit that includes any of the lead introducers described above; and a stimulation lead configured for implantation into a patient. The stimulation lead includes a lead body having a distal end portion and a proximal end portion, electrodes disposed at the distal end portion of the lead body, terminals disposed at the proximal end portion of the lead body, and conductive wires coupling the electrodes electrically to the terminals; wherein the stimulation lead is insertable through the port of the hub of the lead introducer and into the hub lumen of the hub and the open channel of the needle.
Another aspect is an electrical stimulation system that includes the insertion kit described above, a control module configured to electrically couple to the stimulation lead of the insertion kit, and a connector for connecting the stimulation lead to the control module. The control module includes a housing, and an electronic subassembly disposed in the housing. The connector includes a connector housing defining a port for receiving the proximal end portion of the lead body, and connector contacts disposed in the connector housing, the connector contacts configured to couple to the terminals of the stimulation lead when the proximal end portion of the stimulation lead is received by the connector housing.
Non-limiting and non-exhaustive embodiments of the present invention are described with reference to the following drawings. In the drawings, like reference numerals refer to like parts throughout the various figures unless otherwise specified.
For a better understanding of the present invention, reference will be made to the following Detailed Description, which is to be read in association with the accompanying drawings, wherein:
The present invention is directed to the area of implantable stimulation systems and methods of making and using the systems. The present invention is also directed to a lead introducer for facilitating insertion of implantable stimulation leads into patients, as well as methods of making and using the lead introducers and stimulation leads.
Suitable implantable electrical stimulation systems include, but are not limited to, a least one lead with one or more electrodes disposed along a distal end of the lead and one or more terminals disposed along the one or more proximal ends of the lead. Examples of electrical stimulation systems with leads are found in, for example, U.S. Pat. Nos. 6,181,969; 6,295,944; 6,391,985; 6,516,227; 6,609,029; 6,609,032; 6,741,892; 7,244,150; 7,450,997; 7,672,734; 7,761,165; 7,783,359; 7,792,590; 7,809,446; 7,949,395; 7,974,706; 8,831,742; 8,688,235; 6,175,710; 6,224,450; 6,271,094; 6,295,944; 6,364,278; and 6,391,985; U.S. Patent Application Publications Nos. 2007/0150036; 2009/0187222; 2009/0276021; 2010/0076535; 2010/0268298; 2011/0004267; 2011/0078900; 2011/0130817; 2011/0130818; 2011/0238129; 2011/0313500; 2012/0016378; 2012/0046710; 2012/0071949; 2012/0165911; 2012/0197375; 2012/0203316; 2012/0203320; 2012/0203321; 2012/0316615; 2013/0105071; 2011/0005069; 2010/0268298; 2011/0130817; 2011/0130818; 2011/0078900; 2011/0238129; 2011/0313500; 2012/0016378; 2012/0046710; 2012/0165911; 2012/0197375; 2012/0203316; 2012/0203320; and 2012/0203321, all of which are incorporated by reference in their entireties.
The lead 103 can be coupled to the control module 102 in any suitable manner. In at least some embodiments, the lead 103 couples directly to the control module 102. In at least some other embodiments, the lead 103 couples to the control module 102 via one or more intermediate devices. For example, in at least some embodiments one or more lead extensions 224 (see e.g.,
In
The control module 102 typically includes a connector housing 112 and a sealed electronics housing 114. An electronic subassembly 110 and an optional power source 121 are disposed in the electronics housing 114. A control module connector 144 is disposed in the connector housing 112. The control module connector 144 is configured and arranged to make an electrical connection between the lead 103 and the electronic subassembly 110 of the control module 102.
The electrical stimulation system or components of the electrical stimulation system, including one or more of the lead bodies 106 and the control module 102, are typically implanted into the body of a patient. The electrical stimulation system can be used for a variety of applications including, but not limited to, brain stimulation, neural stimulation, spinal cord stimulation, muscle stimulation, and the like.
The electrodes 134 can be formed using any conductive, biocompatible material. Examples of suitable materials include metals, alloys, conductive polymers, conductive carbon, and the like, as well as combinations thereof. In at least some embodiments, one or more of the electrodes 134 are formed from one or more of: platinum, platinum iridium, palladium, palladium rhodium, or titanium. The number of electrodes 134 in each array 133 may vary. For example, there can be two, four, six, eight, ten, twelve, fourteen, sixteen, or more electrodes 134. As will be recognized, other numbers of electrodes 134 may also be used.
The electrodes of the one or more lead bodies 106 are typically disposed in, or separated by, a non-conductive, biocompatible material such as, for example, silicone, polyurethane, polyetheretherketone (“PEEK”), epoxy, and the like or combinations thereof. The lead bodies 106 may be formed in the desired shape by any process including, for example, molding (including injection molding), casting, and the like. The non-conductive material typically extends from the distal end of the one or more lead bodies 106 to the proximal end of each of the one or more lead bodies 106.
Terminals (e.g., 210 in
The electrically conductive wires (“conductors”) may be embedded in the non-conductive material of the lead body 106 or can be disposed in one or more lumens (not shown) extending along the lead body 106. In some embodiments, there is an individual lumen for each conductor. In other embodiments, two or more conductors extend through a lumen. There may also be one or more lumens (not shown) that open at, or near, the proximal end of the lead body 106, for example, for inserting a stylet to facilitate placement of the lead body 106 within a body of a patient. Additionally, there may be one or more lumens (not shown) that open at, or near, the distal end of the lead body 106, for example, for infusion of drugs or medication into the site of implantation of the one or more lead bodies 106. In at least one embodiment, the one or more lumens are flushed continually, or on a regular basis, with saline, epidural fluid, or the like. In at least some embodiments, the one or more lumens are permanently or removably sealable at the distal end.
The control module connector 144 defines at least one port into which a proximal end of the elongated device 200 can be inserted, as shown by directional arrows 212a and 212b. In
The control module connector 144 also includes a plurality of connector contacts, such as connector contact 214, disposed within each port 204a and 204b. When the elongated device 200 is inserted into the ports 204a and 204b, the connector contacts 214 can be aligned with a plurality of terminals 210 disposed along the proximal end(s) of the elongated device(s) 200 to electrically couple the control module 102 to the electrodes (134 of
A lead extension connector 221 is disposed on the lead extension 224. In
In at least some embodiments, the proximal end of the lead extension 224 is similarly configured and arranged as a proximal end of the lead 103 (or other elongated device 200). The lead extension 224 may include a plurality of electrically conductive wires (not shown) that electrically couple the connector contacts 240 to a proximal end 248 of the lead extension 224 that is opposite to the distal end 226. In at least some embodiments, the conductive wires disposed in the lead extension 224 can be electrically coupled to a plurality of terminals (not shown) disposed along the proximal end 248 of the lead extension 224. In at least some embodiments, the proximal end 248 of the lead extension 224 is configured and arranged for insertion into a connector disposed in another lead extension (or another intermediate device). In other embodiments (and as shown in
Returning to
In at least some embodiments, a practitioner may determine the position of the target neurons using recording electrode(s) and then position the stimulation electrode(s) accordingly. In some embodiments, the same electrodes can be used for both recording and stimulation. In some embodiments, separate leads can be used; one with recording electrodes which identify target neurons, and a second lead with stimulation electrodes that replaces the first after target neuron identification. In some embodiments, the same lead may include both recording electrodes and stimulation electrodes or electrodes may be used for both recording and stimulation.
In
Segmented electrodes can be used to direct stimulus current to one side, or even a portion of one side, of the lead. When segmented electrodes are used in conjunction with an implantable pulse generator that delivers current stimulus, current steering can be achieved to more precisely deliver the stimulus to a position around an axis of the lead (i.e., radial positioning around the axis of the lead). Segmented electrodes may provide for superior current steering than ring electrodes because target structures in deep brain stimulation are not typically symmetric about the axis of the distal electrode array. Instead, a target may be located on one side of a plane running through the axis of the lead. Through the use of a segmented electrode array, current steering can be performed not only along a length of the lead but also around a perimeter of the lead. This provides precise three-dimensional targeting and delivery of the current stimulus to neural target tissue, while potentially avoiding stimulation of other tissue.
Examples of leads with segmented electrodes include U.S. Patent Application Publications Nos. 2010/0268298; 2011/0005069; 2011/0078900; 2011/0130803; 2011/0130816; 2011/0130817; 2011/0130818; 2011/0078900; 2011/0238129; 2011/0313500; 2012/0016378; 2012/0046710; 2012/0071949; 2012/0165911; 2012/0197375; 2012/0203316; 2012/0203320; 2012/0203321; 2013/0197602; 2013/0261684; 2013/0325091; 2013/0317587; 2014/0039587; 2014/0353001; 2014/0358209; 2014/0358210; 2015/0018915; 2015/0021817; 2015/0045864; 2015/0021817; 2015/0066120; 2013/0197424; 2015/0151113; 2014/0358207; and U.S. Pat. No. 8,483,237, all of which are incorporated herein by reference in their entireties. A lead may also include a tip electrode and examples of leads with tip electrodes include at least some of the previously cited references, as well as U.S. Patent Application Publications Nos. 2014/0296953 and 2014/0343647, all of which are incorporated herein by reference in their entireties. A lead with segmented electrodes may be a directional lead that can provide stimulation in a particular direction using the segmented electrodes.
Conventional percutaneous implantation techniques often include inserting a lead introducer, such as an epidural needle, into a patient. A lead is then inserted into the lead introducer and the lead introducer is positioned at a target stimulation location. When correctly positioned, the lead introducer is removed from the patient, leaving the lead in place. Often the lead introducer is removed from the patient by sliding the lead introducer off the proximal end of the lead. This action, however, may result in movement of the lead so that it is no longer positioned at the desired stimulation location.
Other percutaneous implantation techniques utilize a lateral release lead introducer that includes a multi-piece insertion needle that enables a lead to be laterally separated from the multi-piece insertion needle instead of sliding the needle off the end of the lead. Examples of lateral release lead introducers are found in, for example, U.S. Patent Application Publication Nos. 2011/0224680, 2014/0039586, 2014/0276927, 2015/0073431, 2015/0073432, and 2016/0317800, all of which are incorporated herein by reference in their entireties. These lateral release lead introducers include an outer needle, an inner needle, a splittable member, and a stylet. The four components of these lateral release lead introducers introduce more complexity than the conventional lead introducer discussed above which only uses one or two components (e.g., an epidural needle and an optional stylet). Lateral release lead introducers can be particularly useful for implanting leads have multiple tails, such as the lead 103 illustrated in
To reduce the number of components and complexity,
As illustrated in
The needle 442 can be made from any suitable material including, but not limited to, stainless steel or other metal. The distal end portion 443 of the needle 442 may have a slanted face 445 with a sharpened end 447 suitable for piercing patient tissue during insertion of the lead introducer 430 into the patient. At least the sharpened end 447 of the needle 442, and preferably the slanted face, extends distally beyond the distal end of the splittable sheath 450, as illustrated in
Returning to
In at least some embodiments, the splittable sheath 450 is arranged to split along the longitudinal axis into a first portion 454 and a second portion 456. In at least some embodiments, the integrated needle/sheath 440 the needle 442 remains attached to the first portion 454 of the splittable sheath 450 when it is split. The second portion 456 of the splittable sheath 450 separates from the needle 442 and also exposes the slot 446 in the needle to allow the lead 103 to be removed from the open channel 444 in the needle.
As illustrated in
In at least some embodiments, an angle 468 between the two pull-apart tabs 464, 466 is less than 180, 120, 90, or 60 degrees. In other embodiments, the pull-apart tabs can be 180 degrees apart, as disclosed in U.S. Patent Application Publication Nos. 2011/0224680, 2014/0039586, 2014/0276927, 2015/0073431, and 2015/0073432, all of which are incorporated herein by reference in their entireties. In yet other embodiments, the pull-apart tabs may extend proximally parallel (or at an acute angle no more than 89, 80, 75, 60, or 45 degrees) to the longitudinal axis of the splittable sheath 450 as disclosed in U.S. Patent Application Publication No. 2016/0317800, incorporated herein by reference in its entirety.
In at least some embodiments, the body 462 of the hub 460 includes, at the proximal end of the body, a small-bore connector 461, such as a Luer fitting, which may be used for coupling with other devices. In at least some embodiments, the body 462 (and the small-bore connector 461, if included) can include one or two slits or weakened regions 463a, 463b between the pull-apart tabs 464, 466 to facilitate separation of the body (and small-bore connector, if included) into two portions when the splittable sheath 462 is split and separated into two regions using the two pull-apart tabs 464, 466, as described above.
In at least some embodiments, the small-bore connector 461, such as a Luer fitting, can facilitate a loss of resistance (LOR) procedure. Because entry into the epidural space is a delicate procedure requiring greater precision than may be obtained via fluoroscopy, LOR is used to insert the tip of the needle 442 just barely into the epidural space. The clinician initially inserts the fully-assembled lead introducer 430 into the patient until the tip is near the epidural space. Then, the needle stylet 470 is removed and a syringe filled with air or saline is connected to the needle 442 through the small-bore connector 461. The clinician slowly advances the needle 442 while applying pressure to the syringe plunger. Before the tip of the needle 442 breaches into the epidural space, the tissue occludes the needle tip, preventing fluid from escaping, and providing resistance to the syringe plunger. Once the tip of the needle 442 breaches the epidural space, the fluid can escape the needle tip and the syringe plunger is easily depressed indicating to the clinician that the needle tip has entered the epidural space.
The hub 460 is separable into two parts 465a, 465b using the at least two pull-apart tabs 464, 466. Separating the hub 460 can also lead to separation of the splittable sheath 450 into the two portions 454, 456. In at least some embodiments, the first portion 465a of the hub 460 is attached to the needle 442 using any suitable method or material. For example, the first portion 465a of the hub 460 can be attached to the needle 442 by adhesive or by overmolding of the first portion 465a of the hub 460 onto the needle 442 or by any other suitable attachment method. The first portion 465a of the hub 460 is also attached to the first portion 454 of the splittable sheath 450 so that, when separation of the two portions 465a, 465b of the hub 460 occurs, the first portions 465a of the hub 460, first portion 454 of the splittable sheath 450, and needle 442 remain fixed together. In addition, when separation of the two portions 465a, 465b of the hub 460 occurs, the second portion 465b of the hub 460 and the second portion 456 of the splittable sheath 450 remain fixed together.
In at least some embodiments, the first portion 454 of the splittable sheath 450 may also be attached to the needle 442 by adhesive or by heat shrinking or melting the first portion 454 of the splittable sheath 450 onto the needle 442 or any other suitable method. Preferably, the attachment of the first portion 454 of the splittable sheath 450 to the needle 442 is sufficient so that the splittable sheath 450 remains attached to the needle 442 during insertion of the lead introducer 430 into the patient. In at least some embodiments, the attachment of the first portion 454 of the splittable sheath 450 to the needle 442 may allow some disengagement of the first portion 454 from the needle 442 after splitting of the hub 460 and splittable sheath 450.
The hub 460 defines a hub lumen 459 that is in communication with the open channel 444 of the needle 442 and through which the needle stylet 470 and lead 103 can be inserted into the open channel of the needle. In at least some embodiments, the hub 460 defines a taper 467 of the hub lumen between the small-bore connector 451 and the region in which the proximal end 441 of the needle 442 is positioned to facilitate a smooth insertion of the needle stylet 470 and lead 103 into the open channel 444 of the needle 442.
In at least some embodiments, the hub 460 further defines a first shoulder 469a against which the proximal end 441 of the needle 442 is positioned and a second should 469b against which the proximal end 457 of the splittable sheath 450 is positioned. In at least some embodiments, the hub 460 further defines one or two gaps 468 in the first and second shoulders 469a, 469b to facilitate reliable splitting of the hub along the intended lines demarcated by the gaps and which may be further demarcated by corresponding slits or weakened regions 463a, 463b (
In at least some embodiments, the needle stylet 470 is shaped such that the needle stylet 470 does not separate laterally from the open channel 444 when the needle stylet 470 is received by the needle 442.
In
In
During implantation of the lead, the outer needle 730 is disposed within the splittable sheath 750. The outer needle includes a needle hub 740 and a body 732. The splittable sheath 750 includes a sheath body 752 and sheath hub 760.
Some of the components (for example, power source 1112, antenna 1118, receiver 1102, and processor 1104) of the electrical stimulation system can be positioned on one or more circuit boards or similar carriers within a sealed housing of an implantable pulse generator, if desired. Any power source 1112 can be used including, for example, a battery such as a primary battery or a rechargeable battery. Examples of other power sources include super capacitors, nuclear or atomic batteries, mechanical resonators, infrared collectors, thermally-powered energy sources, flexural powered energy sources, bioenergy power sources, fuel cells, bioelectric cells, osmotic pressure pumps, and the like including the power sources described in U.S. Pat. No. 11,437,193, incorporated herein by reference in its entirety.
As another alternative, power can be supplied by an external power source through inductive coupling via the optional antenna 1118 or a secondary antenna. The external power source can be in a device that is mounted on the skin of the user or in a unit that is provided near the user on a permanent or periodic basis.
If the power source 1112 is a rechargeable battery, the battery may be recharged using the optional antenna 1118, if desired. Power can be provided to the battery for recharging by inductively coupling the battery through the antenna to a recharging unit 1116 external to the user. Examples of such arrangements can be found in the references identified above.
In one embodiment, electrical current is emitted by the electrodes 134 on the lead body to stimulate nerve fibers, muscle fibers, or other body tissues near the electrical stimulation system. A processor 1104 is generally included to control the timing and electrical characteristics of the electrical stimulation system. For example, the processor 1104 can, if desired, control one or more of the timing, frequency, amplitude, width, and waveform of the pulses. In addition, the processor 1104 can select which electrodes can be used to provide stimulation, if desired. In some embodiments, the processor 1104 may select which electrode(s) are cathodes and which electrode(s) are anodes. In some embodiments, the processor 1104 may be used to identify which electrodes provide the most useful stimulation of the desired tissue.
Any processor can be used and can be as simple as an electronic device that, for example, produces pulses at a regular interval or the processor can be capable of receiving and interpreting instructions from an external programming unit 1108 that, for example, allows modification of pulse characteristics. In the illustrated embodiment, the processor 1104 is coupled to a receiver 1102 which, in turn, is coupled to the optional antenna 1118. This allows the processor 1104 to receive instructions from an external source to, for example, direct the pulse characteristics and the selection of electrodes, if desired.
In one embodiment, the antenna 1118 is capable of receiving signals (e.g., RF signals) from an external telemetry unit 1106 which is programmed by a programming unit 1108. The programming unit 1108 can be external to, or part of, the telemetry unit 1106. The telemetry unit 1106 can be a device that is worn on the skin of the user or can be carried by the user and can have a form similar to a pager, cellular phone, or remote control, if desired. As another alternative, the telemetry unit 1106 may not be worn or carried by the user but may only be available at a home station or at a clinician's office. The programming unit 1108 can be any unit that can provide information to the telemetry unit 1106 for transmission to the electrical stimulation system 1100. The programming unit 1108 can be part of the telemetry unit 1106 or can provide signals or information to the telemetry unit 1106 via a wireless or wired connection. One example of a suitable programming unit is a computer operated by the user or clinician to send signals to the telemetry unit 1106.
The signals sent to the processor 1104 via the antenna 1118 and receiver 1102 can be used to modify or otherwise direct the operation of the electrical stimulation system. For example, the signals may be used to modify the pulses of the electrical stimulation system such as modifying one or more of pulse width, pulse frequency, pulse waveform, and pulse amplitude. The signals may also direct the electrical stimulation system 1100 to cease operation, to start operation, to start charging the battery, or to stop charging the battery. In other embodiments, the stimulation system does not include an antenna 1118 or receiver 1102 and the processor 1104 operates as programmed.
Optionally, the electrical stimulation system 1100 may include a transmitter (not shown) coupled to the processor 1104 and the antenna 1118 for transmitting signals back to the telemetry unit 1106 or another unit capable of receiving the signals. For example, the electrical stimulation system 1100 may transmit signals indicating whether the electrical stimulation system 1100 is operating properly or not or indicating when the battery needs to be charged or the level of charge remaining in the battery. The processor 1104 may also be capable of transmitting information about the pulse characteristics so that a user or clinician can determine or verify the characteristics.
The above specification, examples and data provide a description of the manufacture and use of the composition of the invention. Since many embodiments of the invention can be made without departing from the spirit and scope of the invention, the invention also resides in the claims hereinafter appended.
This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application Ser. No. 62/807,351, filed Feb. 19, 2019, which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3330278 | Santomieri | Jul 1967 | A |
3359978 | Smith | Dec 1967 | A |
3568660 | Crites et al. | Mar 1971 | A |
3677243 | Nerz | Jul 1972 | A |
4166469 | Littleford | Sep 1979 | A |
4355646 | Kallok et al. | Oct 1982 | A |
4449973 | Luther | May 1984 | A |
RE31855 | Osborne | Mar 1985 | E |
4512351 | Pohndorf | Apr 1985 | A |
4608986 | Beranek et al. | Sep 1986 | A |
4808157 | Coombs | Feb 1989 | A |
5125904 | Lee | Jun 1992 | A |
5255691 | Otten | Oct 1993 | A |
5312355 | Lee | May 1994 | A |
5320602 | Karpiel | Jun 1994 | A |
5380290 | Makower et al. | Jan 1995 | A |
5409469 | Schaerf | Apr 1995 | A |
5441504 | Pohndorf et al. | Aug 1995 | A |
5713867 | Morris | Feb 1998 | A |
5741233 | Riddle et al. | Apr 1998 | A |
5752937 | Otten et al. | May 1998 | A |
5755693 | Walker et al. | May 1998 | A |
5931863 | Griffin, III et al. | Aug 1999 | A |
6080141 | Castro et al. | Jun 2000 | A |
6181969 | Gord | Jan 2001 | B1 |
6251119 | Addis | Jun 2001 | B1 |
6358460 | Hunt, Jr. et al. | Mar 2002 | B1 |
6454744 | Spohn et al. | Sep 2002 | B1 |
6494860 | Rocamora et al. | Dec 2002 | B2 |
6516227 | Meadows et al. | Feb 2003 | B1 |
6582390 | Sanderson | Jun 2003 | B1 |
6609029 | Mann et al. | Aug 2003 | B1 |
6609032 | Woods et al. | Sep 2003 | B1 |
6641564 | Kraus | Nov 2003 | B1 |
6645178 | Junker et al. | Nov 2003 | B1 |
6712791 | Lui et al. | Mar 2004 | B2 |
6741892 | Meadows et al. | May 2004 | B1 |
6749600 | Levy | Jun 2004 | B1 |
6758854 | Butler et al. | Jul 2004 | B1 |
6869416 | Windheuser et al. | Mar 2005 | B2 |
6939327 | Hall et al. | Sep 2005 | B2 |
7001396 | Glazier et al. | Feb 2006 | B2 |
7014626 | Sanderson | Mar 2006 | B2 |
7101353 | Lui et al. | Sep 2006 | B2 |
7192433 | Osypka et al. | Mar 2007 | B2 |
7244150 | Brase | Jul 2007 | B1 |
7359755 | Jones et al. | Apr 2008 | B2 |
7437193 | Parramon | Oct 2008 | B2 |
7450997 | Pianca et al. | Nov 2008 | B1 |
7524305 | Moyer | Apr 2009 | B2 |
7672734 | Anderson | Mar 2010 | B2 |
7744571 | Fisher et al. | Jun 2010 | B2 |
7761165 | He | Jul 2010 | B1 |
7783359 | Meadows | Aug 2010 | B2 |
7792590 | Pianca et al. | Sep 2010 | B1 |
7809446 | Meadows | Oct 2010 | B2 |
7887733 | Moyer | Feb 2011 | B2 |
7909798 | Osypka | Mar 2011 | B2 |
7938806 | Fisher et al. | May 2011 | B2 |
7941227 | Barker | May 2011 | B2 |
7949395 | Kuzma | May 2011 | B2 |
7974706 | Moffitt et al. | Jul 2011 | B2 |
7985232 | Potter et al. | Jul 2011 | B2 |
7993305 | Ye et al. | Aug 2011 | B2 |
8043263 | Helgeson et al. | Oct 2011 | B2 |
8105287 | Fisher et al. | Jan 2012 | B2 |
8105315 | Johnson et al. | Jan 2012 | B2 |
8112159 | Harris et al. | Feb 2012 | B2 |
8137317 | Osypka | Mar 2012 | B2 |
8147456 | Fisher et al. | Apr 2012 | B2 |
8175710 | He | May 2012 | B2 |
8180461 | Mamo et al. | May 2012 | B2 |
8224450 | Brase | Jul 2012 | B2 |
8271094 | Moffitt et al. | Sep 2012 | B1 |
8273059 | Nardeo et al. | Sep 2012 | B2 |
8295944 | Howard et al. | Oct 2012 | B2 |
8348899 | Chesnin et al. | Jan 2013 | B2 |
8364278 | Pianca et al. | Jan 2013 | B2 |
8377006 | Tal et al. | Feb 2013 | B2 |
8382715 | Nardeo et al. | Feb 2013 | B2 |
8391985 | McDonald | Mar 2013 | B2 |
8583237 | Bedenbaugh | Nov 2013 | B2 |
8688235 | Pianca et al. | Apr 2014 | B1 |
8831742 | Pianca et al. | Sep 2014 | B2 |
8849422 | Pianca | Sep 2014 | B2 |
9510857 | Barker | Dec 2016 | B2 |
9931109 | Burckhardt et al. | Apr 2018 | B2 |
9987435 | Colantonio | Jun 2018 | B2 |
20020111617 | Cosman et al. | Aug 2002 | A1 |
20050021119 | Sage et al. | Jan 2005 | A1 |
20050055027 | Yeung et al. | Mar 2005 | A1 |
20050107861 | Harris et al. | May 2005 | A1 |
20050113860 | Keidar | May 2005 | A1 |
20070150036 | Anderson | Jun 2007 | A1 |
20080300538 | Schweikert et al. | Dec 2008 | A1 |
20090187222 | Barker | Jul 2009 | A1 |
20090248111 | Pianca et al. | Oct 2009 | A1 |
20090254019 | Gehl et al. | Oct 2009 | A1 |
20090259283 | Brandt et al. | Oct 2009 | A1 |
20090276021 | Meadows et al. | Nov 2009 | A1 |
20100076535 | Pianca et al. | Mar 2010 | A1 |
20100268298 | Moffitt et al. | Oct 2010 | A1 |
20110004267 | Meadows | Jan 2011 | A1 |
20110005069 | Pianca | Jan 2011 | A1 |
20110054402 | Tanabe et al. | Mar 2011 | A1 |
20110078900 | Pianca et al. | Apr 2011 | A1 |
20110130803 | McDonald | Jun 2011 | A1 |
20110130816 | Howard et al. | Jun 2011 | A1 |
20110130817 | Chen | Jun 2011 | A1 |
20110130818 | Chen | Jun 2011 | A1 |
20110218549 | Barker | Sep 2011 | A1 |
20110224680 | Barker | Sep 2011 | A1 |
20110224681 | McDonald | Sep 2011 | A1 |
20110230893 | Barker | Sep 2011 | A1 |
20110238129 | Moffitt et al. | Sep 2011 | A1 |
20110313500 | Barker et al. | Dec 2011 | A1 |
20120016378 | Pianca et al. | Jan 2012 | A1 |
20120046710 | DiGiore et al. | Feb 2012 | A1 |
20120071949 | Pianca et al. | Mar 2012 | A1 |
20120165911 | Pianca | Jun 2012 | A1 |
20120197375 | Pianca et al. | Aug 2012 | A1 |
20120202928 | Barker et al. | Aug 2012 | A1 |
20120203316 | Moffitt et al. | Aug 2012 | A1 |
20120203320 | DiGiore et al. | Aug 2012 | A1 |
20120203321 | Moffitt et al. | Aug 2012 | A1 |
20120316615 | DiGiore et al. | Dec 2012 | A1 |
20120323254 | Bonde et al. | Dec 2012 | A1 |
20130053851 | Schmitz et al. | Feb 2013 | A1 |
20130105071 | DiGiore et al. | May 2013 | A1 |
20130197424 | Bedenbaugh | Aug 2013 | A1 |
20130197602 | Pianca et al. | Aug 2013 | A1 |
20130261684 | Howard | Oct 2013 | A1 |
20130317587 | Barker | Nov 2013 | A1 |
20130325091 | Pianca et al. | Dec 2013 | A1 |
20140039586 | Barker et al. | Feb 2014 | A1 |
20140039587 | Romero | Feb 2014 | A1 |
20140073926 | Rajendran et al. | Mar 2014 | A1 |
20140276927 | Barker | Sep 2014 | A1 |
20140296953 | Pianca et al. | Oct 2014 | A1 |
20140343647 | Romero et al. | Nov 2014 | A1 |
20140353001 | Romero et al. | Dec 2014 | A1 |
20140358207 | Romero | Dec 2014 | A1 |
20140358209 | Romero et al. | Dec 2014 | A1 |
20140358210 | Howard et al. | Dec 2014 | A1 |
20150018915 | Leven | Jan 2015 | A1 |
20150021817 | Romero et al. | Jan 2015 | A1 |
20150045864 | Howard | Feb 2015 | A1 |
20150066120 | Govea | Mar 2015 | A1 |
20150073431 | Barker | Mar 2015 | A1 |
20150073432 | Barker | Mar 2015 | A1 |
20150151113 | Govea et al. | Jun 2015 | A1 |
20160317800 | Barker | Nov 2016 | A1 |
20170340891 | Boggs et al. | Nov 2017 | A1 |
Number | Date | Country |
---|---|---|
2008686 | Dec 2008 | EP |
8900436 | Jan 1989 | WO |
03011361 | Feb 2003 | WO |
Entry |
---|
International Search Report and Written Opinion for PCT Application No. PCT/US2020/018378 dated Aug. 20, 2020. |
Invitation to Pay Additional Fees for PCT Application No. PCT/US2020/018378 mailed Jun. 24, 2020. |
Number | Date | Country | |
---|---|---|---|
20200261714 A1 | Aug 2020 | US |
Number | Date | Country | |
---|---|---|---|
62807351 | Feb 2019 | US |